Pathogenic intestinal bacteria adhesion sites

Adhesion sites for pathogenic intestinal bacteria comprise various structures—primarily specific carbohydrate residues, proteins, or glycoproteins—on the surface of intestinal epithelial cells or within the mucus layer that overlies them[3][5]. Pathogenic bacteria utilize surface structures (such as fimbriae, pili, or specific adhesins) to bind these sites, initiating colonization, infection, and sometimes invasion[1][3][5]. This process can be inhibited or competitively excluded by probiotics that bind to the same sites, or by direct blockade using adhesion-inhibiting molecules[1][5]. The specific identity of an adhesion site varies by both host and pathogen type (e.g., different bacteria target different glycoproteins or receptors on host cells), and these sites are not, in themselves, single protein/gene products or pharmacological targets. Rather, “adhesion sites” summarizes the concept of the host cell loci that mediate microbial attachment. Additional details: - Probiotics exert some of their beneficial effects by competitively occupying these adhesion sites, thereby preventing pathogenic adherence and infection[1][5]. - Known bacterial adhesins that mediate binding include various mucus-binding proteins (Mub, MucBP), S-layer proteins, and pili such as type IV pili or SpaCBA pili[1][3]. - Pathogenic bacteria such as enteropathogenic E. coli and Listeria monocytogenes use similar mechanisms to adhere to intestinal epithelium[5]. In summary, "Pathogenic intestinal bacteria adhesion sites" describes a class of host structures, not a distinct molecular target, and is not appropriate as a canonical therapeutic target entry[1][3][5].

Other names

adhesion sites for pathogenic intestinal bacteriabacterial adhesion targets in intestineintestinal epithelial adhesion sites

Competitive binding (by probiotics or mimetics) and Blockade by adhesion inhibitors